This article is more than 5 years old. Information may no longer be current.
SeraCare launches HCV RNA linearity panel
Click Here to Manage Email Alerts
SeraCare Life Sciences announced the launch of the company’s proprietary AccuSpan HCV RNA Linearity Panel designed to monitor HCV RNA recovery at defined intervals, according to a press release.
Using its AccuPlex recombinant technology, SeraCare developed the eight-member panel from serial dilutions of high-titer recombinant HCV genotype 1 with established reactivity for HCV RNA. The company qualified the design against WHO standards.
Compared with other technologies that package viral RNA into a bacteriophage, AccuPlex recombinants resemble the “wild-type mammalian pathogenic virus,” per the release, and mimics a real patient sample throughout the diagnostic workflow.
According to the press release, SeraCare will present the AccuPlex recombinant technology at the American Association for Clinical Chemistry 2018 meeting in Chicago.
Reference: www.seracare.com